Patent intelligence · US
US 8188259
Oligonucleotide-containing pharmacological compositions and their use
Oligonucleotide-containing pharmacological compositions and their use
Patent details — US 8188259
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 29, 2012
- Expiration
- May 24, 2032
- Applicant
- Lakewood Amedex, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K2800/74, A61K38/00, A61K8/606
Quick answer
US 8188259 (Oligonucleotide-containing pharmacological compositions and their use) is held by Lakewood Amedex, Inc.. Status: granted. Granted May 29, 2012. Expires May 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lakewood Amedex, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2800/74, A61K38/00, A61K8/606, A61P, A61P1/00
More from Lakewood Amedex, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12156883
Bisphosphocin gel formulations and uses thereof
granted -
US 12054509
Antimicrobial compounds, compositions, and uses thereof
granted -
US 12030908
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11795192
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11377468
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11123357
Methods and compositions for treating oral mucositis
granted -
US 11096954
Bisphosphocin gel formulations and uses thereof
granted -
US 10981943
Antimicrobial compounds, compositions, and uses thereof
granted
Frequently asked questions
What is US patent 8188259?
US 8188259 (Oligonucleotide-containing pharmacological compositions and their use) is held by Lakewood Amedex, Inc.. Status: granted. Granted May 29, 2012. Expires May 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8188259?
Lakewood Amedex, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 8188259 expire?
Our index shows an expiration date of May 24, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.